Leading up to the Antibody Engineering Event, we'll be sharing the posters that will be featured in the Exhibit Hall. Antibody Engineering & Therapeutics will take place December 8-12, 2013 in Huntington Beach, California. For more information the program, download the agenda. If you'd like to join us, as a reader of this blog, when you register to join us and mention code XD13172BLOGJP, you'll save 20% off the standard rate!Poster: Development of anti-GDF-8 antibody with improved efficacy: impact of epitope and antibody engineering.
Presenter: Michelle Mader, Pfizer IncAbout the Poster: Myostatin (GDF8) is a known negative regulator of muscle growth with the expression specific to skeletal muscle. GDF8 knock-out animals (mice, dogs and cows) develop skeletal muscles that are 100-200% larger than normal through hyperplasia and hypertrophy. Therapeutic approaches have largely been focused on the neutralization of myostatin signaling through its high affinity receptor, ActRIIB, to increase muscle growth which could be beneficial in muscle frailty indications. A new myostatin neutralizing antibody with unique properties will be described. Co-crystallization of GDF8 with the humanized anti-GDF8 Fab revealed a unique 1:2 stoichiometery of antibody binding to mature GDF8 dimer which was supported by subsequent in vitro studies. Structure based rational design enabled further optimization, resulting in a potent antibody biotherapeutic with improved in vivo efficacy, safety and stability.
Do you have new research to share with your industry colleagues? Your poster can be featured in the Antibody Engineering Exhibit hall as well! Find out how here. The deadline for poster submissions is November 1.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment